 TOKYO, April 19, 2021 PRNewswire -- Eisai Co., Ltd. Headquarters: Tokyo, CEO: Haruo Naito, Eisai and Biogen Inc. Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, Biogen today announced the publication of an article, A Randomized, Double-Blind Phase 2b Proof of Concept Clinical Trial in Early Alzheimers Disease with Lecanemab, an Anti-Aβ Protofibril Antibody, in the peer-reviewed journal Alzheimers Research and Therapy. 